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Since 1948 when Farber and his colleagues17 
introduced aminopterin in the treatment of 
acute leukemia of childhood, the field of 
cancer chemotherapy has grown spectacu-
larly. Today, a vast selection of drugs are 
available to treat every variety of cancer. 
One of the effects of many of these agents 
is impairment of antibody synthesis and cell 
mediated immunity. These immunosuppres-
sive effects have been used therapeutically 
to prevent and control rejection of organ 
transplants. The immunosuppressive agents 
have also been used to treat a variety of 
clinical states including chronic hepatitis, 
ulcerative colitis, Crohn's disease, glomerulo-
nephritis, sarcoidosis, bronchial asthma, 
uveitis, rheumatoid arthritis, psoriasis and 
other chronic skin diseases. 
Apart from their cytotoxic side effects 
the cancer chemotherapeutic agents have 
direct or indirect mutagenic, teratogenic and 
oncogenic effects. These have been frequently 
demonstrated in experimental animals and in 
lower forms of life.4 • 7, 16, 30, 32, 33, 35. 5B, 60, 7G 
The present report is concerned with their 
potential oncogenic properties in man. Evi-
dence has been accumulated from three 
groups of patients: 1) Organ transplant 
recipients treated with immunosuppressive 
compounds; 2) Patients with a variety of 
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nonmalignant diseases treated with immuno-
suppressive agents; 3) Patients with malig-
nancies who received cancer chemotherapy. 
ORGAN TRANSPLANT RECIPIENTS 
Since the Fall of 1968 an informal Tumor 
Registry has been maintained in Denver to 
record all cases of cancer encountered in 
organ homograft recipients.49--52 Tumors 
were encountered in three groups of patients: 
Cancers that appeared after transplanta-
tion; cancers inadvertently transmitted with 
the organ homograft; cancers that were 
present before transplantation. The role 
played by the immunosuppressive drugs in 
each of these categories must now be con-
sidered. 
Cancers That Appeared After 
Transplantation 
In previous reports4!l-5~. 68 we have indi-
cated that an organ transplant recipient 
maintained on chronic immunosuppressive 
therapy has a 5 to 6% chance of developing 
a malignant tumor. This risk is approxi-
mately 100 times greater than in individuals 
in the general population in the same age 
range. Through September 15, 1972 we 
collected details of 122 cases from transplant 
centers throughout the world (Table 1) and 
incomplete information on approximately 
another 25 cases. The 122 patients had 125 
types of tumor of which 76 were of epithelial 
origin (61 %) and 49 (39 %) were mesen-
chymal. The most common epithelial lesions 
werc various skin cancers (27 cases-36% ), 
carcinomas of the cervix (11 cases-14 % ) 
and carcinomas of the lip (11 cases-14 % ) . 
The most common mesenchymal tumors 
were various types of solid lymphoma (42 
cases-86%) of which the most prominent 
group were the reticulum cell sarcomas (30 
cases-61 % ). A most unusual feature of 
the lymphomas was their predilection for the 
central nervous system which occurred in 20 
of 41 cases (49%). In 17 instances (41 % ) 
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TABLE 1 
Types of Tumors 
Epithelial Tumors 
(76 in 74 patients) 
Skin cancers 27' 
Carcinoma of cervix 11 
Carcinoma of lip 11' 
Carcinoma of lung 4 
Carcinoma of colon 2 
Hepatoma 2 
Endometrial carcinoma 
Carcinoma of bile ducts 2 
Dysgerminoma of ovary 1 
Embryonal cell carcinoma of 
testis 
Adenocarcinoma of breast 2 
Carcinoma of floor of mouth 
Widespread squamous cell 
carcinoma (primary site 
unknown) 
Carcinoma of stomach 1 
Carcinoma of pancreas 1t 
Carcinoma of kidney 2 
Malignant melanoma of retina 
Carcinoma of thyroid gland 
Carcinoma possibly of suprarenal 
origin 
Miscellaneous undifferentiated 
carcinoma 3t 
Mesenchymal Tumors 
(49 in 48 patients) 
Reticulum cell sarcoma 
Kaposi's sarcoma 
Unclassified lymphoma 
Hodgkin's disease 
Lymphosarcoma 
Plasma cell lymphoma 
Lymphoreticular malignancy 
Lymphoma 
Leukemia 
Rhabdomyosarcoma 
Leiomyosarcoma 
Synovial sarcoma 
Oligodendroglioma 
30:1: 
4:1: 
3 
1 
2 
1 
2 
* One patient had a carcinoma of the lip and a carcinoma of the forehead. 
t One patient had a well differentiated carcinoma of the pancreas and a markedly anaplastic carcinoma in the 
mediastinum. 
* One patient had a reticulum cell sarcoma of the brain and Kaposi's sarcoma of the skin. 
the central nervous system was the only area 
affected. These figures contrast with a 
0.04% to 1.5% involvement of the central 
nervous system in two large series. 55, 57 
The cancers generally occurred in young 
people (average age 36, range 8 to 70 years) 
of which 37% were over the age of 40 years. 
The average time of appearance of the 
tumors following transplantation was 28 
months (range 1 to 92 months). In 16 in-
stances (13 %) the neoplasms made their 
appearance within the first 4 months after 
transplantation. It is possible that at least 
some of these tumors or even some of those 
with a later appearance were already present 
at the time of transplantation, but were small 
and undetected, and grew rapidly under the 
influence of the immunosuppressive therapy. 
It is important to consider whether the 
cancers were inadvertently transplanted from 
the organ donors. The 122 recipients re-
ceived their transplants from 137 donors, 
62 living volunteers and 75 cadavers. None 
of the living donors has manifested evidence 
of cancer during follow-up periods as long 
as 9% years. Two cadaver donors had me-
dulloblastomas, whereas the recipients sub-
sequently developed a gluteal reticulum cell 
sarcoma and a gastric leiomyosarcoma re-
spectively. The tumors in donor and recipi-
ent were morphologically distinct and there 
was probably no etiologic connection unless 
they were both caused by an oncogenic virus 
that was transmitted with the donor kidney. 
A further cadaver donor had had carcinoma 
of the colon resected five years previously 
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but was apparently free of tumor at the time 
of transplantation. The recipient developed 
a cerebral reticulum cell sarcoma. 
Almost all of the patients received immu-
nosuppression with azathioprine and predni-
sone. Other immunosuppressive agents used 
were ALG (38 cases, in 2 cases after the 
appearance of tumor), Actinomycin (39 
cases), roentgen therapy to the homograft 
(45 cases), splenectomy (41 cases), thymec-
tomy (7 cases), thymic irradiation (2 cases), 
thoracic duct lymph drainage (7 cases), en-
dolymphatic radiation (1 case), total body 
irradiation (1 case), cyclophosphamide (3 
cases), methotrexate (1 case), 6-mercapto-
purine (1 case), and azaserine (1 case). 
Treatment of the epithelial lesions of skin, 
lip and uterine cervix followed conventional 
lines and was usually successful. However, 
many patients with cancers of the skin tended 
to have multiple lesions and in two instances 
the tumors involved the regional lymph 
nodes. In two instances not included in the 
present series because of incomplete data, 
the skin tumors metastasized and killed the 
patients. Epithelial tumors other than those 
mentioned above had a much worse prog-
nosis and either caused or contributed to the 
patients' deaths. The overall survival in pa-
tients with epithelial cancers was 44 of 74 
(59 % ). The outlook for recipients with mes-
enchymal neoplasms was even more gloomy 
in that only 11 of 48 patients (23%) are 
still living. Experience thus far is limited, but 
it appears that conventional cancer therapy 
combined with reduction or cessation of im-
munosuppression may permit the patient's 
immune system to recover and destroy the 
neoplasm. Five of the current survivors with 
highly malignant tumors were treated in this 
way with apparent eradication of the lesion. 
One of these patients is still alive more than 
four years after treatment of a cerebral lym-
phoma. In addition, two patients with wide-
spread tumors treated in this fashion, who 
died of infection or homograft failure, were 
found to be free of cancer at autopsy. 
Transplanted Cancers 
Table 2 is a summary of cases in which 
kidneys were removed from donors who had 
cancer at the time of donation or who mani-
fested evidence of the disease some months 
TABLE 2 
Fate of Patients Who Received Kidneys 
from Donors with Cancer 
(Excluding primary cerebral tumors) 
Total number of recipients 33 
Recipients with no evidence of cancer 19 
Cancer in transplanted kidney only 4 
Cancer involved kidney and adjacent 
structures 
Cases with distant spread of cancer 
Died of metastases 
Rejection of tumor 
Died of other causes 
4 
3 
2 
8 
afterwards. Five of the 33 transplants were 
from living donors and 28 from cadavers, 
of which the great majority had widespread 
cancer. In each case the transplanted kidney 
appeared to be grossly free of tumor. How-
ever, in some cases macroscopic or micro-
scopic evidence of cancer was found in the 
contralateral kidney and in several instances 
this was an indication for removal of the 
transplant. 
Two of the living donors were apparently 
free of tumor at the time of nephrectomy but 
subsequently developed cancer of the rectum 
and pancreas respectively. It is questionable 
whether the tumors were present at the time 
of donation and both recipients are well at 
13 and 18 months post-transplantation re-
spectively. In two further instances "free" 
kidneys removed from patients who were 
operated on for cancer were used. One was 
from a patient with carcinoma of the colon 
compressing the ureter, while the sccond was 
the seat of a hypernephroma. This latter kid-
ney was deliberately transplanted into a phy-
sician dying of renal failure in whom no 
other suitable donor was available. Severe 
rejection of the homograft occurred at 12 
weeks in spite of immunosuppression. How-
ever, the neoplastic tissue survived and was 
vigorously invading adjacent structures at the 
time of the patient's death three weeks later. 
The fifth living donor was found to have 
a nodule in the kidney at operation. The 
nodule was removed and, as a frozen section 
examination suggested a benign lesion, the 
kidney was transplanted. However, a per-
manent section raised the suspicion of ma-
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lignancy, and the kidney was removed at 48 
hours. The recipient remains free of tumor 
17 months after a second transplant and im-
munosuppressive therapy. 
Of the 33 recipients, 19 showed no evi-
dence of tumor either at autopsy or during 
follow-ups which have ranged from 1 to 32 
months. Presumably the kidneys were either 
free of cancer, or transplanted malignant 
cells failed to become established in the host. 
In four more patients, tumor was found in 
the kidneys when they were removed within 
the first 16 days after transplantation. In two 
more recipients (including the patient with 
hypernephroma mentioned above) the kid-
ney and adjacent structures were involved by 
cancer, while in eight more patients there 
was also evidence of distant spread of the 
neoplasm. Four of these eight died of the 
transplanted cancer and in a fifth, metastatic 
tumor undoubtedly contributed to the pa-
tient's death. Immunosuppression was dis-
continued in the remaining three patients and 
the cancers apparently underwent rejec-
tion.79, 82 One of these recipients is well 97 
months post-transplantation despite further 
immunosuppressive therapy given for two 
subsequent renal transplants, each of which 
functioned for 12 to 18 months. The second 
patient died several months after cessation 
of immunosuppression and was found to 
have no evidence of tumor at autopsy. The 
third recipient had a suspected cerebral me-
tastasis, but no evidence of this or of residual 
cancer in the kidney was found at autopsy 
five months after immunosuppression was 
discontinued. 
Cancers Present Before Transplantation 
Fifty three patients had cancers within the 
five years preceding transplantation (Table 
3) . The table does not include cases of 
leukemia or advanced cancers treated with 
bone marrow or splenic transplantation, nor 
cases with a follow-up of less than two 
months. A number of patients who under-
went liver replacement for hepatoma are 
therefore excluded from this study. In 14 of 
the 53 cases the tumor did not involve the 
organ undergoing replacement (skin 6; blad-
der 2; thyroid 1; parathyroid 1; parotid 1; 
breast 1; cervix of uterus 1; recurrent leio-
myosarcoma of small bowel 1). In 39 cases 
transplantation was performed specifically 
for treatment of cancer of one or both kid-
neys (21 cases), primary or metastatic can-
cer of the liver (17 cases) and carcinoma 
TABLE 3 
Effect of Immunosuppression on 53 Patients with Pre-Existing Cancers· 
Type of 
Cancer 
Liver cancers 
Renal and urethral cancers 
Laryngeal cancer 
A. Total of all cases who 
had transplantation for 
cancer 
B. Cancers incidental to 
transplantation 
C. Total of aI/ cases 
Number 
of Cases 
17 
21 
39 
14 
53 
Development 
of Unrelated 
No Recurrence De Novo 
Recurrence or Metastases Tumors 
7 
12 
19 
9 
28 
9 
7t 
1 
17t 
5 
2t 
3t 
3t 
3t 
Tumor Not 
Removed, 
Remained 
Unchanged 
• Treated 5 years or less before transplantation, excluding cases of leukemia and advanced cancers treated by bone 
marrow or splenic transplantation; and cases with a follow·up of less than 2 months. 
t One patient died of metastases of a urethral carcinoma but also had a de novo skin cancer. 
~--~ ~---------~--------
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of the larynx (1 case). Three of the kidney 
patients underwent transplantation for renal 
failure and an incidental carcinoma of the 
kidney was found in two and of the ureter 
in one. Where transplantation was performed 
in the treatment of cancer, the neoplasm ap-
peared to be localized and resectable so that 
there was hope of obtaining a "cure." 
Nine (64 %) of the 14 patients with a 
variety of neoplasms remained free of tumor 
for 7 to 60 months after transplantation and 
5 (36%) developed recurrent or metastatic 
cancer in a follow-up of 2 to 36 months. 
In the 21 patients who had transplantation 
for renal or ureteral neoplasia, 7 (33%) 
had recurrent or metastatic tumor. One of 
these recipients had a pulmonary metastasis 
resected at 3 months and is apparently free 
of tumor 56 months after transplantation. 
Twelve patients (57%) were free of cancer 
after follow-ups ranging from 2 to 48 
months. Three of the 21 recipients (14%) 
developed de novo tumors of a completely 
different type from their original neoplasms, 
but one of these died of metastases of the 
ureteral carcinoma. 
Of the 17 patients who underwent trans-
plantation for hepatic tumors, 9 (53%) died 
with recurrent tumor in follow ups ranging 
from 2~ to 14 months, and 4 (23%) died 
of other causes 2Y2 to 4~ months after 
transplantation and manifested no evidence 
of cancer at autopsy. One patient (6%) in 
whom the original tumor was not removed 
died of infection at 8 months and showed 
no apparent progression of the neoplasm 
during this time. Three patients (18%) are 
alive 30 to 42 months after transplantation 
and are apparently free of tumor. The indi-
vidual who underwent laryngeal transplan-
tation died 10 months later of recurrent 
tumor. 
Thus, of the 53 recipients, 28 (53%) 
have no evidence of tumor in follow-ups 
ranging from 2 to 42 months. Twenty-two 
patients (41 %) developed recurrent or met-
astatic cancers, 3 (6%) (one of whom also 
manifested metastasis of a ureteral carci-
noma) developed de novo tumors of a com-
pletely different type from their original neo-
plasms, and in one (2%) the non-resected 
tumor remained unchanged. 
PATIENTS WITH NONMALIGNANT 
DISEASES TREATED WITH 
IMMUNOSUPPRESSIVE AGENTS 
Thirty patients suffering from chronic cold 
hemagglutinin disease,80 rheumatoid arthri-
tis,19 the nephrotic syndrome,64 systemic lu-
pus erythematosus,37, 41 ulcerative colitis48 or 
psoriasis13. 24, 44. 54, 56. 63 were treated with 
immunosuppressive agents and developed 
cancer (Table 4), In the case of the first 
four conditions it might be argued that the 
TABLE 4 
Development of Cancers in 30 Patients with Nonmalignant Diseases Treated 
with Immunosuppressive Agents 
No. of 
Cases 
Disease Treated 
Chronic cold hemagglutinin 
disease 
Rheumatoid arthritis 4 
Nephrotic syndrome 2 
S.L.E. 2 
Ulcerative colitis 1 
Psoriasis 20 
• In some cases more than one agent was used. 
Major Agent Used" 
Chlorambucil 
Cyclophosphamide 
Azathioprine 
Azathioprine 
Azathioprine 
Methotrexate (19); 
Aminopterin (1) 
Type of Cancer 
Reticulum cell sarcoma (1) 
Lymphoma (2); leukemia (2) 
Lymphoma (1); 
bronchial carcinoma (1) 
Lymphoma (1); 
malignant melanoma (1) 
Carcinoma of colon (1) 
Various visceral cancers (17); 
skin cancers (3) 
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immunosuppressive agents played no role in 
the development of the tumors as these are 
autoimmune diseases in which an increased 
incidence of cancer, particularly lymphoma, 
has been reported.22, 50 Similarly, the admin-
istration of azathioprine to the patient with 
ulcerative colitis may have been purely for-
tuitous in a condition which is frequently 
complicated by carcinoma of the colon. 
However, these arguments do not apply to 
psoriasis which is not usually associated with 
cancer, unless the patient has been treated 
with a carcinogenic agent such as arsenic. 
The development of cancer in twenty psori-
atic patients chronically treated with metho-
trexate or with the closely related compound, 
aminopterin, must therefore be regarded with 
the gravest suspicion, 
PATIENTS WIm MALIGNANCIES 
WHO RECEIVED CANCER 
CHEMOTHERAPY 
Table 5 is a summary of patients who re-
ceived prolonged cancer chemotherapy for 
one type of neoplasm and subsequently de-
veloped a new cancer of a different type.1-3, 
5, 9, 11, ]2, ]5, 20, 25, 26, 29, 31, 34, 36, 38-40, 42, 43, 
45-47, 53, 61, 62, 66, 73, 76, 78, 81 Were the anti-
cancer drugs the cause of these tumors or 
could these have occurred spontaneously? It 
is well recognized that a patient with one 
type of cancer is more prone to develop a 
second neoplasm. Furthermore, certain tu-
mor associations are widely accepted, includ-
ing polycythemia rubra vera or myelofibrosis 
(with myeloid metaplasia) with granulocytic 
leukemia; the relationship between solid lym-
phoma and lymphocytic leukemia; and the 
termination of chronic myelogenous leukemia 
in acute myeloblastic leukemia. A few of the 
cases in Table 5 may be of this type. How-
ever, certain associations are decidedly un-
common and raise the strong suspicion that 
the cancer chemotherapeutic agents, while 
controlling the original neoplasm, may have 
contributed to the development of the second 
type of tumor. The development of acute 
leukemia in 21 patients with multiple mye-
loma who were chronically treated with anti-
cancer drugs, most commonly melphalan, is 
one striking example. Another is the devel-
opment of a solid lymphoma in nine cases 
of chronic granulocytic leukemia. McPhe-
dran and Heath42 have emphasized the rarity 
of acute leukemia in chronic lymphocytic 
leukemia and have mentioned the possibility 
that the acute leukemia represents a second 
malignancy rather than a true "blast" phase 
of chronic lymphocytic leukemia. Numerous 
isolated cases of a second tumor which ap-
peared while the patient was receiving che-
motherapy for cancer are shown in Table 5. 
In many of these reports the authors raised 
the question whether the second tumor was 
induced by the very agent which had con-
trolled the first cancer. 
DISCUSSION 
The cancer chemotherapeutic agents exert 
their effects usually by interference with 
DNA or RNA metabolism and may seriously 
disrupt the normal function of the cells. 
These cytostatic or frankly cytotoxic effects 
are seen not only in cancer cells but also in 
other vulnerable cells of the host. In experi-
mental animals it has been shown that the 
agents and their immunosuppressive deriva-
tives may also cause chromosome breaks, de-
pression of immune responses, mutagenic, 
teratogenic and even encogenic effects.4, 23, 
32, 33, 35, 50, 58, 60, 72, 75, 77 It is indeed a para-
dox that agents which destroy cancer or arrest 
its growth may themselves be oncogenic. 
In man some of these undesirable side ef-
fects have been demonstrated. Chromosome 
breaks,27. 28, 59 nuclear abnormalities, 30, 74 
cytologic dysplasia8 , 18, 23, 34, 43, 45, 65, 77 and 
teratogenic effects14 , 30, 67, 69 have also been 
described. 
Several questions have to be answered. 
Do the anti-cancer and immunosuppressive 
agents cause cancer in man? If so, by what 
mechanism? What is the effect of these 
agents on existing cancers? 
The answer to the first question is pro-
vided mainly by experience gained in organ 
homograft recipients. In the University of 
Colorado-Denver Veterans Administration 
Hospital series we have repeatedly reported 
a 5 to 6 % incidence of de novo cancers in 
renal homograft recipients treated with 
chronic immunosuppressive therapy,4D-52, 68 
At the present time we have found de novo 
tumors in 22 of 390 recipients (5.6%) with 
a potential follow up of from 6 months to 
almost 10 years. The additional 100 cases 
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TABLE 5 
New Malignancies in 61 Patients with Cancer Treated with Chemotherapy 
Initial Cancer 
Multiple myeloma 
Chronic granulocytic 
leukemia 
Chronic lymphocytic 
leukemia 
Polycythemia rubra 
vera 
Lymphosarcoma 
Hodgkin's disease 
Choriocarci noma 
Carcinoma of ovary 
Adenocarcinoma of 
lung 
Primary myelo-
fibromatosis 
Number 
of Cases 
21 
13 
3 
9 
4 
3 
3 
3 
Major Agent 
Used' 
Melphalan; 
Cyclophosphamide 
Busulfan; 
Multiple; 
Urethane 
Chlorambucil 
Melphalan; 
Triethylene 
melamine 
Busulfan 
Cyclophosphamide 
Multiple; 
Cyclophosphamide 
Methotrexate 
Thiotepa; 
Methotrexate 
Thiotepa 
Cyclophosphamide 
• I n some cases more than one agent was used. 
Number 
of Cases 
19 
2 
10 
2 
1 
3 
7 
4 
2 
3 
2 
1 
t One patient developed acute leukemia and a basal cell carcinoma of the skin. 
Number 
Second Cancer of Cases 
Acute leukemia; 21 t 
Basal cell carcinoma 1t 
of skin 
Reticulum cell 
sarcoma 
Lymphosarcoma 
Hodgkin's disease 
Carcinoma of vulva 
Carcinoma of breast 
Carcinoma of 
pancreas 
Carcinoma of lung 
Myelomonocytic 
leukemia 
Acute myeloblastic 
leukemia 
Acute leukemia 
4 
3 
2 
1 
Acute leukemia 6 
Glioblastoma 
multiforme 
Carcinoma of prostate 
Carcinoma of colon 
Carcinoma of skin 2 
Carcinoma of stomach 1 
Carcinoma of bladder 
Carcinoma of bladder 2 
Carcinoma of lung 1 
Carcinoma of cervix 2 
in situ 
Hodgkin's disease 
Acute leukemia 
Acute leukemia 
Reticulum cell 
sarcoma 
3 
collected from transplant centers throughout 
the world confirm these findings. 
These conclusions are reinforced by ex-
perience gained with neoplasms inadvertently 
transplanted with kidneys obtained from do-
nors with cancer. It is very rarely possible 
to transplant a malignant tumor from one 
healthy human to another. The tumor cells 
are recognized as "foreign" by the host's de-
fenses and are readily destroyed. However, 
if the normal defense mechanisms are im-
paired by chronic immunosuppression it is 
possible for the transferred malignant cells 
to become established in the transplanted 
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organ, invade the surrounding tissues and 
metastasize widely. If the immunosuppres-
sive therapy is discontinued before the can-
cer has completely sapped the host's resis-
tance, it is possible for the immune defenses 
to recover and to reject the cancer cells. 
This method of treatment was successfully 
employed in several cases reported in this 
paper. Furthermore, it may also be applica-
ble to the management of the more aggres-
sive de novo tumors which arise in organ 
homograft recipients and which fail to re-
spond to conventional cancer therapy. 
The concept that tumors may arise in in-
dividuals under chronic immunosuppressive 
therapy is further strengthened by reports 
concerning nontransplant patients treated 
with these agents. This applies particularly 
to sufferers from psoriasis who received 
chronic treatment with methotrexatc or ami-
nopterin. 
How do the immunosuppressive or cancer 
chemotherapeutic agents cause malignant 
tumors? The answer here is speculative, but 
several possibilities exist. First, the drugs 
may be directly oncogenic. Second, the com-
pounds may potentiate the effects of various 
environmental carcinogens such as tobacco, 
sunlight or radiation. Third, the agents may 
cripple the surveillance function of the lym-
phoreticular system.6 • 70 Mutations, some of 
which are potentially oncogenic, are con-
stantly occurring either spontaneously or in 
response to various stimuli. The mutant cells 
are normally eliminated by the lymphoretic-
ular system. However, if its function is im-
paired by chronic immunosuppressive ther-
apy, malignant mutations may survive and 
cause overt cancers. Fourth, the immuno-
suppressive drugs may permit oncogenic vi-
ruses to become established and cause ma-
lignant tumors. 
While there is unequivocal evidence that 
the anti-cancer and immunosuppressive 
agents may cause de novo neoplasms, their 
effects on patients with pre-existing tumors 
are not so clearly defined. In organ trans-
plant recipients with cancer there is a 41 % 
likelihood of recurrence or metastases of the 
original tumor and a 6 % incidence of an 
unrelated de novo neoplasm. In the present 
state of our knowledge it is not possible to 
determine whether the former figure is 
merely a reflection of the natural history of 
the cancers or is contributed to by chronic 
immunosuppressive therapy. In this connec-
tion there is an interesting observation by 
Thomas71 who treated several patients with 
acute lymphatic leukemia with total body 
irradiation, bone marrow transplantation 
and immunosuppression. In several of the 
recipients, leukemia recurred but in two in-
stances the lesion involved the transplanted 
donor cells. 
In the case of advanced cancers treated 
with chemotherapy there are a number of 
reports suggesting that while the original 
cancer had been controlled the long-term 
chemotherapy may have caused new cancers. 
Many of these cases are summarized in the 
present paper. No doubt there are numerous 
additional cases which have not been re-
ported. The subject is a very complex one 
as we have to take into consideration the 
increased likelihood of a patient with one 
cancer developing a second neoplasm; the 
tcndency for one form of cancer to change 
to another related type; and the influence of 
other therapeutic agents such as radiotherapy 
which may be oncogenic. In the present se-
ries (Table 5) the three most commonly used 
compounds were melphalan, cyclophospha-
mide and busulfan-all alkylating agents. 
These have radiomimetic actions and are 
known to be mutagenic and carcinogenic in 
laboratory animals. 4• 33, 75 The same could 
bc said for several other anti-cancer drugs 
which are not alkylating agents. 
While cancer chemotherapy has had some 
notable successes, as in the treatment 
of choriocarcinomas, Burkitt's lymphoma, 
Wilm's tumor and acute lymphatic leukemia, 
the overall results have been rather disap-
pointing. These have been blamed on un-
responsiveness of the tumor to a particular 
agent, or on subsequent development of 
resistance to the compound by the cancer 
cells, or to the toxic effects of the agents 
used. Another factor, which has received 
relatively scant attention, is the prolonged 
immunosuppressive effect of the agents when 
administered for prolonged periods. Could 
this be the explanation for the observation 
that a better objective response and longer 
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survival was observed when chemotherapy 
was given intermittently rather than con-
tinuously?lO. 21 
The finding that cancer patients treated 
with chemotherapy may develop entirely 
new tumors is more of academic than of 
practical importance and represents the 
price the patient has to pay for months or 
years of relief from the original cancer. 
However, several important lessons do 
emerge from this study. First, immunosup-
pressive agents should not be used in non-
malignant diseases such as psoriasis or rheu-
matoid arthritis unless all other forms of 
therapy have failed to provide relief. Second, 
in organ transplantation, donors with cancer 
should not be used except in cases with 
primary tumors of the central nervous system 
which seldom spread to other organs, and 
even here there may be an increased risk. 
Third, when a cancer arises in an immuno-
suppressed patient it may be useful to with-
draw or reduce the immunosuppressive 
therapy in the hope that the host defenses 
may recover and destroy the neoplasm. 
Fourth, the studies emphasize the impor-
tance of the immune system in dealing with 
cancer, and suggest that research on immu-
notherapy should be vigorously pursued. 
SUMMARY 
Cancer chemotherapeutic and immuno-
suppressive agents may be directly or indi-
rectly oncogenic. Organ transplant recipients 
on chronic immunosuppressive therapy have 
a 5 to 6 % chance of developing a de novo 
malignant tumor. Neoplastic cells may be 
inadvertently transplanted from donors with 
cancer. If transferred to an immunosup-
pressed host such cells may become estab-
lished and grow within the transplanted 
organ, invade the surrounding structures 
and produce distant metastases. If immuno-
suppression is discontinued before the can-
cer completely saps the host's resistance, the 
immune defenses may recover and destroy 
the cancer. 
De novo malignant tumors may arise 
when immunosuppression is used in treat-
ment of diseases such as psoriasis, rheuma-
toid arthritis or the nephrotic syndrome. 
The risk of this complication should serve 
as a deterrent to the use of this therapy in 
these conditions except when all other meth-
ods of treatment have failed. Organ trans-
plantation and immunosuppressive therapy 
in patients with pre-existing cancers have a 
41 % risk of recurrence or metastasis of the 
original tumor and a 6% risk of the devel-
opment of unrelated de novo tumors. 
There is much circumstantial evidence 
suggesting that cancer chemotherapy, while 
allowing control of one cancer, may permit 
or induce the growth of a second tumor. 
This risk may be of little practical impor-
tance but it is a matter of great biologic 
interest in terms of the etiology and poten-
tial treatment of cancer. One hope for the 
ultimate eradication of cancer appears to be 
in the field of immunotherapy. 
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